Target intelligence / Profile preview

Steroidal Neuromuscular Blocking Agent - Sugammadex Complex (NMBA-Sugammadex Complex)

Target: NMBA-Sugammadex Complex
Molecular classification: Drug Complex, Host-Guest Complex

Overview

The Steroidal Neuromuscular Blocking Agent - Sugammadex Complex is a non-covalent, 1:1 complex formed between steroidal neuromuscular blocking agents (NMBAs) like rocuronium or vecuronium and sugammadex, a modified γ-cyclodextrin. This complexation effectively inactivates the NMBA, preventing it from binding to nicotinic acetylcholine receptors at the neuromuscular junction, thereby reversing the effects of neuromuscular blockade induced during anesthesia. The complex is pharmacologically inactive and readily excreted, contributing to a rapid and predictable recovery from muscle relaxation. While generally safe, potential safety concerns include hypersensitivity reactions to sugammadex and the risk of inadequate reversal if the complex formation is incomplete.

Other names: Rocuronium-Sugammadex ComplexVecuronium-Sugammadex ComplexAminosteroidal NMBA-Sugammadex Complex

Mechanism of action

Encapsulation of steroidal neuromuscular blocking agents, preventing binding to acetylcholine receptors and reversing neuromuscular blockade.

Biological functions

Drug inactivationNeuromuscular blockade reversal

Disease associations

AnesthesiaSurgical recovery

Safety considerations

Potential for anaphylaxisRisk of residual neuromuscular blockade if reversal is inadequateHypersensitivity reactions to sugammadexOverdosing of sugammadex leading to unbound sugammadex in circulation

Interacting drugs

Rocuronium

3 more in the full profile.

Beyond the preview

Go deeper on Steroidal Neuromuscular Blocking Agent - Sugammadex Complex (NMBA-Sugammadex Complex).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Steroidal Neuromuscular Blocking Agent - Sugammadex Complex (NMBA-Sugammadex Complex).

Explore the full profile